TEANECK, NJ and TITUSVILLE, NJ — February 15, 2002 — Eisai Inc. and Janssen Pharmaceutica Inc. announced today that the U.S. Food and Drug Administration has approved the expanded use of the proton pump inhibitor, Aciphex® (rabeprazole sodium), to include the treatment of daytime and nighttime heartburn and other symptoms associated with gastroesophageal reflux disease (GERD).
לכתבה המלאה לחץ על הקישור
SOURCE: Eisai Inc. and Janssen Pharmaceutica Inc.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!